Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.

Abayasingam A, Leung P, Eltahla A, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd A, Rodrigo C.

Infect Genet Evol. 2019 Mar 7. pii: S1567-1348(18)30936-5. doi: 10.1016/j.meegid.2019.02.032. [Epub ahead of print]

PMID:
30853512
2.

Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.

Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; InC3 Collaborative.

Clin Infect Dis. 2019 Feb 28. pii: ciz162. doi: 10.1093/cid/ciz162. [Epub ahead of print]

PMID:
30816419
3.

Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.

Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, Grillon C, Luhmann N, Mason K, McLean E, Trooskin S, Treloar C, Grebely J.

Int J Drug Policy. 2019 Feb 8;66:87-93. doi: 10.1016/j.drugpo.2019.01.012. [Epub ahead of print]

PMID:
30743093
4.

Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC.

Lisovsky I, Kant S, Tremblay-McLean A, Isitman G, Kiani Z, Dupuy FP, Gilbert L, Bruneau J, Shoukry NH, Lebouché B, Bernard NF.

J Leukoc Biol. 2019 Mar;105(3):551-563. doi: 10.1002/JLB.4A0617-242RRR. Epub 2019 Jan 30.

PMID:
30698860
5.

Genomic variability of within-host hepatitis C variants in acute infection.

Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA; InC3 Collaborative.

J Viral Hepat. 2019 Apr;26(4):476-484. doi: 10.1111/jvh.13051. Epub 2019 Jan 22.

PMID:
30578702
6.

Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation.

Parlato M, Charbit-Henrion F, Elie AN, Begue B, Guegan N, Bruneau J, Khater S, Macintyre E, Picard C, Frédéric RL, Le Bourhis L, Allez M, Goulet O, Cellier C, Hermine O, Cerf-Bensussan N, Malamut G.

Gastroenterology. 2019 Mar;156(4):1206-1210.e1. doi: 10.1053/j.gastro.2018.11.065. Epub 2018 Dec 15. No abstract available.

7.

Loss of ARHGEF1 causes a human primary antibody deficiency.

Bouafia A, Lofek S, Bruneau J, Chentout L, Lamrini H, Trinquand A, Deau MC, Heurtier L, Meignin V, Picard C, Macintyre E, Alibeu O, Bras M, Molina TJ, Cavazzana M, André-Schmutz I, Durandy A, Fischer A, Oksenhendler E, Kracker S.

J Clin Invest. 2019 Mar 1;129(3):1047-1060. doi: 10.1172/JCI120572. Epub 2019 Feb 4.

8.

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.

Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°.

Gut. 2018 Nov 17. pii: gutjnl-2018-317371. doi: 10.1136/gutjnl-2018-317371. [Epub ahead of print]

PMID:
30448772
9.

The evolving drug epidemic of prescription opioid injection and its association with HCV transmission among people who inject drugs in Montréal, Canada.

Bruneau J, Arruda N, Zang G, Jutras-Aswad D, Roy É.

Addiction. 2019 Feb;114(2):366-373. doi: 10.1111/add.14487. Epub 2018 Dec 9.

PMID:
30399197
10.

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.

Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravčík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P.

Lancet Infect Dis. 2018 Dec;18(12):1397-1409. doi: 10.1016/S1473-3099(18)30469-9. Epub 2018 Oct 29.

11.

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.

Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ; D3FEAT Study Group.

Int J Drug Policy. 2018 Dec;62:94-103. doi: 10.1016/j.drugpo.2018.10.004. Epub 2018 Oct 29.

PMID:
30384028
12.

Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.

Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group.

Int J Drug Policy. 2018 Dec;62:14-23. doi: 10.1016/j.drugpo.2018.08.013. Epub 2018 Oct 22.

PMID:
30352330
13.

Feline low-grade alimentary lymphoma: an emerging entity and a potential animal model for human disease.

Paulin MV, Couronné L, Beguin J, Le Poder S, Delverdier M, Semin MO, Bruneau J, Cerf-Bensussan N, Malamut G, Cellier C, Benchekroun G, Tiret L, German AJ, Hermine O, Freiche V.

BMC Vet Res. 2018 Oct 11;14(1):306. doi: 10.1186/s12917-018-1635-5. Review.

14.

A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues.

Derrieux C, Trinquand A, Bruneau J, Verkarre V, Lhermitte L, Alcantara M, Villarese P, Meresse B, Sibon D, Hermine O, Brousse N, Molina T, Cellier C, Cerf-Bensussan N, Malamut G, Macintyre E.

J Mol Diagn. 2019 Jan;21(1):111-122. doi: 10.1016/j.jmoldx.2018.08.006. Epub 2018 Sep 28.

PMID:
30268943
15.

Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance.

Rosenberg BR, Depla M, Freije CA, Gaucher D, Mazouz S, Boisvert M, Bédard N, Bruneau J, Rice CM, Shoukry NH.

PLoS Pathog. 2018 Sep 17;14(9):e1007290. doi: 10.1371/journal.ppat.1007290. eCollection 2018 Sep.

16.

Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Liver Int. 2019 Jan;39(1):20-30. doi: 10.1111/liv.13949. Epub 2018 Sep 22. Review.

PMID:
30157316
17.

Guided by gaze: Prioritization strategy when navigating through a virtual crowd can be assessed through gaze activity.

Meerhoff LA, Bruneau J, Vu A, Olivier AH, Pettré J.

Acta Psychol (Amst). 2018 Oct;190:248-257. doi: 10.1016/j.actpsy.2018.07.009. Epub 2018 Aug 24.

PMID:
30149239
18.

Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada.

Jutras-Aswad D, Le Foll B, Bruneau J, Wild TC, Wood E, Fischer B.

Can J Psychiatry. 2019 Feb;64(2):82-87. doi: 10.1177/0706743718790955. Epub 2018 Jul 22. No abstract available.

PMID:
30033757
19.

Diagnostic Yield of Next-Generation Sequencing in Very Early-Onset Inflammatory Bowel Diseases: A Multicenter Study.

Charbit-Henrion F, Parlato M, Hanein S, Duclaux-Loras R, Nowak J, Begue B, Rakotobe S, Bruneau J, Fourrage C, Alibeu O, Rieux-Laucat F, Lévy E, Stolzenberg MC, Mazerolles F, Latour S, Lenoir C, Fischer A, Picard C, Aloi M, Amil Dias J, Ben Hariz M, Bourrier A, Breuer C, Breton A, Bronski J, Buderus S, Cananzi M, Coopman S, Crémilleux C, Dabadie A, Dumant-Forest C, Egritas Gurkan O, Fabre A, Fischer A, German Diaz M, Gonzalez-Lama Y, Goulet O, Guariso G, Gurcan N, Homan M, Hugot JP, Jeziorski E, Karanika E, Lachaux A, Lewindon P, Lima R, Magro F, Major J, Malamut G, Mas E, Mattyus I, Mearin LM, Melek J, Navas-Lopez VM, Paerregaard A, Pelatan C, Pigneur B, Pinto Pais I, Rebeuh J, Romano C, Siala N, Strisciuglio C, Tempia-Caliera M, Tounian P, Turner D, Urbonas V, Willot S, Ruemmele FM, Cerf-Bensussan N.

J Crohns Colitis. 2018 May 18. doi: 10.1093/ecco-jcc/jjy068. [Epub ahead of print]

20.

Paediatric mastocytosis: long-term follow-up of 53 patients with whole sequencing of KIT. A prospective study.

Meni C, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Jais JP, Hadj-Rabia S, Bruneau J, Fraitag S, Hanssens K, Dubreuil P, Hermine O, Bodemer C.

Br J Dermatol. 2018 Oct;179(4):925-932. doi: 10.1111/bjd.16795. Epub 2018 Sep 9.

PMID:
29787623
21.

HLA-F on HLA-Null 721.221 Cells Activates Primary NK Cells Expressing the Activating Killer Ig-like Receptor KIR3DS1.

Kiani Z, Dupuy FP, Bruneau J, Lebouché B, Zhang CX, Jackson E, Lisovsky I, da Fonseca S, Geraghty DE, Bernard NF.

J Immunol. 2018 Jul 1;201(1):113-123. doi: 10.4049/jimmunol.1701370. Epub 2018 May 9.

PMID:
29743316
22.

A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder.

El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lespérance F, Lespérance P, Ouellet-Plamondon C, Bruneau J, Jutras-Aswad D.

Int Clin Psychopharmacol. 2018 Sep;33(5):268-273. doi: 10.1097/YIC.0000000000000223.

PMID:
29738425
23.

The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.

Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D.

Contemp Clin Trials. 2018 Jun;69:21-27. doi: 10.1016/j.cct.2018.04.001. Epub 2018 Apr 5.

PMID:
29627621
24.

Human ALPI deficiency causes inflammatory bowel disease and highlights a key mechanism of gut homeostasis.

Parlato M, Charbit-Henrion F, Pan J, Romano C, Duclaux-Loras R, Le Du MH, Warner N, Francalanci P, Bruneau J, Bras M, Zarhrate M, Bègue B, Guegan N, Rakotobe S, Kapel N, De Angelis P, Griffiths AM, Fiedler K, Crowley E, Ruemmele F, Muise AM, Cerf-Bensussan N.

EMBO Mol Med. 2018 Apr;10(4). pii: e8483. doi: 10.15252/emmm.201708483.

25.

Management of opioid use disorders: a national clinical practice guideline.

Bruneau J, Ahamad K, Goyer MÈ, Poulin G, Selby P, Fischer B, Wild TC, Wood E; CIHR Canadian Research Initiative in Substance Misuse.

CMAJ. 2018 Mar 5;190(9):E247-E257. doi: 10.1503/cmaj.170958. No abstract available.

26.

Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration.

Bonnard D, Le Rouzic E, Eiler S, Amadori C, Orlov I, Bruneau JM, Brias J, Barbion J, Chevreuil F, Spehner D, Chasset S, Ledoussal B, Moreau F, Saïb A, Klaholz BP, Emiliani S, Ruff M, Zamborlini A, Benarous R.

J Biol Chem. 2018 Apr 20;293(16):6172-6186. doi: 10.1074/jbc.M117.816793. Epub 2018 Mar 5.

PMID:
29507092
27.

Socio-economic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015.

Mehraj V, Cox J, Lebouché B, Costiniuk C, Cao W, Li T, Ponte R, Thomas R, Szabo J, Baril JG, Trottier B, Côté P, LeBlanc R, Bruneau J, Tremblay C, Routy JP; Montreal Primary HIV-Infection Study Group.

J Int AIDS Soc. 2018 Feb;21(2). doi: 10.1002/jia2.25034.

28.

Tranquilizer misuse among active cocaine users: Predictors of initiation.

Roy É, Arruda N, Jutras-Aswad D, Berbiche D, Motta-Ochoa R, Bruneau J.

Drug Alcohol Rev. 2018 May;37(4):520-526. doi: 10.1111/dar.12666. Epub 2018 Feb 6.

PMID:
29405461
29.

Antibody-mediated rejection in pediatric small bowel transplantation: Capillaritis is a major determinant of C4d positivity in intestinal transplant biopsies.

Rabant M, Racapé M, Petit LM, Taupin JL, Aubert O, Bruneau J, Barbet P, Goulet O, Chardot C, Suberbielle C, Lacaille F, Canioni D, Duong Van Huyen JP.

Am J Transplant. 2018 Sep;18(9):2250-2260. doi: 10.1111/ajt.14685. Epub 2018 Mar 24.

PMID:
29397036
30.

Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity.

Smith LK, Boukhaled GM, Condotta SA, Mazouz S, Guthmiller JJ, Vijay R, Butler NS, Bruneau J, Shoukry NH, Krawczyk CM, Richer MJ.

Immunity. 2018 Feb 20;48(2):299-312.e5. doi: 10.1016/j.immuni.2018.01.006. Epub 2018 Jan 23.

31.

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.

PMID:
29310928
32.

Examining the Association Between Psychiatric Disorders and Cocaine Binges: Results From the COSMO Study.

Juteau LC, Roy É, Berbiche D, Arruda N, Bruneau J, Jutras-Aswad D.

J Addict Med. 2018 Mar/Apr;12(2):136-142. doi: 10.1097/ADM.0000000000000378.

PMID:
29283956
33.

Successful haematopoietic stem cell transplantation in a case of pulmonary alveolar proteinosis due to GM-CSF receptor deficiency.

Frémond ML, Hadchouel A, Schweitzer C, Berteloot L, Bruneau J, Bonnet C, Cros G, Briand C, Magnani A, Pochon C, Delacourt C, Cavazzana M, Moshous D, Fischer A, Blanche S, Blic J, Neven B.

Thorax. 2018 Jun;73(6):590-592. doi: 10.1136/thoraxjnl-2017-211076. Epub 2017 Dec 20. No abstract available.

PMID:
29263235
34.

Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas.

Lemonnier F, Poullot E, Dupuy A, Couronné L, Martin N, Scourzic L, Fataccioli V, Bruneau J, Cairns RA, Mak TW, Bernard OA, de Leval L, Gaulard P.

Haematologica. 2018 Mar;103(3):e115-e118. doi: 10.3324/haematol.2017.167973. Epub 2017 Dec 14. No abstract available.

35.

Estimates are not enough: scaling-up interventions to improve the health of people who inject drugs.

Prins M, Bruneau J.

Lancet Glob Health. 2017 Dec;5(12):e1162-e1163. doi: 10.1016/S2214-109X(17)30430-8. No abstract available.

36.

Expression Profiles of Ligands for Activating Natural Killer Cell Receptors on HIV Infected and Uninfected CD4⁺ T Cells.

Tremblay-McLean A, Bruneau J, Lebouché B, Lisovsky I, Song R, Bernard NF.

Viruses. 2017 Oct 12;9(10). pii: E295. doi: 10.3390/v9100295.

37.

The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative.

Esmaeili A, Mirzazadeh A, Morris MD, Hajarizadeh B, Sacks HS, Maher L, Grebely J, Kim AY, Lauer G, Cox AL, Hellard M, Dietze P, Bruneau J, Shoukry NH, Dore GJ, Lloyd AR, Prins M, Page K; InC3 Collaborative.

Clin Infect Dis. 2018 Jan 6;66(1):20-28. doi: 10.1093/cid/cix768.

38.

Association between binge drug use and suicide attempt among people who inject drugs.

Fournier C, Ghabrash MF, Artenie A, Roy E, Zang G, Bruneau J, Jutras-Aswad D.

Subst Abus. 2018;39(3):315-321. doi: 10.1080/08897077.2017.1389800. Epub 2017 Nov 13.

PMID:
28991519
39.

HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulin-like Receptor (KIR) B motifs; Contribution of KIR B motif encoded genes to NK cell responsiveness.

Jackson E, Zhang CX, Kiani Z, Lisovsky I, Tallon B, Del Corpo A, Gilbert L, Bruneau J, Thomas R, Côté P, Trottier B, LeBlanc R, Rouleau D, Tremblay C, Tsoukas CM, Routy JP, Ni X, Mabanga T, Bernard NF; Montreal Primary Infection Study Group.

PLoS One. 2017 Sep 22;12(9):e0185160. doi: 10.1371/journal.pone.0185160. eCollection 2017.

40.

Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M.

Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021. doi: 10.1002/14651858.CD012021.pub2. Review.

41.

Foot self-management for adults with diabetes in western countries: a scoping review protocol.

Stevens K, Bruneau J, Moralejo D.

JBI Database System Rev Implement Rep. 2017 Sep;15(9):2249-2256. doi: 10.11124/JBISRIR-2016-003269. Review.

PMID:
28902691
42.

Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M.

Addiction. 2018 Mar;113(3):545-563. doi: 10.1111/add.14012. Epub 2017 Oct 23. Review.

43.

Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy.

Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, Treloar C; International Network on Hepatitis in Substance Users; International Network on Hepatitis in Substance Users.

Int J Drug Policy. 2017 Sep;47:26-33. doi: 10.1016/j.drugpo.2017.08.001. No abstract available.

44.

Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression.

Marçais A, Waast L, Bruneau J, Hanssens K, Asnafi V, Gaulard P, Suarez F, Dubreuil P, Gessain A, Hermine O, Pique C.

Oncotarget. 2016 Nov 26;8(32):52256-52268. doi: 10.18632/oncotarget.13665. eCollection 2017 Aug 8.

45.

Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder.

Mallet V, Bruneau J, Zuber J, Alanio C, Leclerc-Mercier S, Roque-Afonso AM, Kraft ARM, Couronné L, Roulot D, Wedemeyer H, Albert ML, Hillon P, Laroche L, Pol S, Hermine O.

J Hepatol. 2017 Dec;67(6):1334-1339. doi: 10.1016/j.jhep.2017.08.011. Epub 2017 Aug 30.

PMID:
28860025
46.

Helicobacter bilis-Associated Suppurative Cholangitis in a Patient with X-Linked Agammaglobulinemia.

Degand N, Dautremer J, Pilmis B, Ferroni A, Lanternier F, Bruneau J, Hermine O, Blanche S, Nassif X, Lortholary O, Lecuit M.

J Clin Immunol. 2017 Oct;37(7):727-731. doi: 10.1007/s10875-017-0437-z. Epub 2017 Aug 31.

PMID:
28856582
47.

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I, Norton BL, Litwin AH, Dore GJ; International Network on Hepatitis in Substance Users.

Int J Drug Policy. 2017 Sep;47:51-60. doi: 10.1016/j.drugpo.2017.05.019. Epub 2017 Jul 3.

48.

High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.

Puzhko S, Roy É, Jutras-Aswad D, Artenie AA, Fortier E, Zang G, Bruneau J.

Int J Drug Policy. 2017 Sep;47:61-68. doi: 10.1016/j.drugpo.2017.05.027. Epub 2017 Jun 27.

PMID:
28666636
49.

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:230-238. doi: 10.1016/j.drugpo.2017.05.040. Epub 2017 Jun 19.

PMID:
28633998
50.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:177-186. doi: 10.1016/j.drugpo.2017.05.020. Epub 2017 Jun 16.

PMID:
28624134

Supplemental Content

Loading ...
Support Center